CING Earnings — Cingulate Inc. Common Stock Post-ER Performance | BigEarnings
CING — Cingulate Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$4.16
Market Cap$55.2M
P/E—
52W Range$3.20 – $11.89
Next Earnings2026-08-18
About Cingulate Inc. Common Stock
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
